Differential Effects of Risperidone, Olanzapine, Clozapine, and Conventional Antipsychotics on Type 2 Diabetes: Findings From a Large Health Plan Database
The DOI matches its Crossref record.
Abstract
BACKGROUND: Case series suggest that some antipsychotics may induce or exacerbate type 2 diabetes. This study measured the association of antipsychotic treatments with diabetes at a population level. METHOD: Claims data for psychosis patients (ICD-CM-9 290.xx-299.xx) within health plans encompassing 2.5 million individuals were analyzed. Patients reporting preexisting type 2 diabetes up to 8 months prior to observation were excluded. The frequency of newly reported type 2 diabetes in untreated patients and among patients treated with antipsychotics from 5 categories (risperidone, olanzapine, clozapine, and high-potency and low-potency conventionals) was compared. Logistic regression models compared the odds of diabetes based on exposure to each of the antipsychotic categories. RESULTS: Based on 12 months of exposure, the odds of type 2 diabetes for risperidone-treated patients (odds ratio = 0.88, 95% CI = 0.372 to 2.070) was not significantly different from that for untreated patients, whereas patients receiving other antipsychotics had a significantly greater risk of diabetes than untreated patients (p < .05): olanzapine, 3.10 (95% CI = 1.620 to 5.934); clozapine, 7.44 (95% CI = 0.603 to 34.751); high-potency conventionals, 2.13 (95% CI = 1.097 to 4.134); and low-potency conventionals, 3.46 (95% CI = 1.522 to 7.785). Older age and greater use of non-antipsychotic psychotropic medications also contributed to risk of type 2 diabetes. Olanzapine also showed significantly higher (p < .01) odds of diabetes associated with increasing dose. CONCLUSION: Consistent with previously published literature, these data suggest that olanzapine, clozapine, and some conventional antipsychotics appear to increase the risk of acquiring or exacerbating type 2 diabetes and that the effect may vary by drug. In contrast to these agents, risperidone was not associated with an increased risk of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Serotonin regulates pancreatic beta cell mass during pregnancy
Kim, H., Toyofuku, Y., Lynn, F. C., Chak, E., Uchida, T., Mizukami, H., Fujitani, Y., Kawamori, R., Miyatsuka, T., Kosaka, Y., et al. (2010) · Nature Medicine · doi:10.1038/nm.2173 · Cited by 586
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P., Evins, A. E., Hayden, D., Weber, M. T., Anderson, E. J., Allison, D. B., Daley, T. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.19 · Cited by 319
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315
Smith, M., Hopkins, D., Peveler, R. C., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 275
Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia
Enger, C., Weatherby, L., Reynolds, R. F., Glasser, D. B., & Walker, A. M. (2004) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000105996.62105.07 · Cited by 215
“The prevalence of noninsulin-dependent diabetes mellitus may vary with the antipsychotic medication used (Gianfrancesco et al., 2002; Goldstein et al., 1999; Hägg et al., 1998; Henderson et al., 2000; Wirshing et al., 1998).”
BackgroundIncidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Leslie, D. L., & Rosenheck, R. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1709 · Cited by 212
Nielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Atypical antipsychotics and glucose dysregulation: a systematic review
Jin, H., Meyer, J. M., & Jeste, D. V. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.024 · Cited by 195
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Barnett, A. H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A., Hill, J., Millar, H., Peveler, R., Rees, A., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107075509 · Cited by 165
Treatment with antipsychotics and the risk of diabetes in clinical practice
Kessing, L. V., Thomsen, A. F., Mogensen, U. B., & Andersen, P. K. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076935 · Cited by 152
“19,20 The rates of incident diabetes increased during periods with a higher number of prescriptions for second-as well as first-generation anti-psychotics (Table 2) and during polypharmacy (Table 4) suggesting that development of diabetes was related to the antipsychotic drugs per se rather than to…”
Antipsychotics and diabetes: review of non-prospective data
Haddad, P. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s80 · Cited by 71
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Citrome, L. L., Holt, R. I., Zachry, W. M., Clewell, J. D., Orth, P. A., Karagianis, J. L., & Hoffmann, V. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k141 · Cited by 64
The unchanging mortality gap for people with schizophrenia.
Chwastiak, L. A., & Tek, C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61072-2 · Cited by 41
Chue, P., & Kovacs, C. S. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00063.x · Cited by 32
Jerrell, J., McIntyre, R., & Tripathi, A. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.3.2 · Cited by 31
Sumiyoshi, T., Roy, A., Anil, A. E., Jayathilake, K., Ertugrul, A., & Meltzer, H. Y. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000126668.67820.00 · Cited by 28
Metadata
- Authors
- Gianfrancesco, F. D., Grogg, A. L., Mahmoud, R. A., Wang, R.-H., & Nasrallah, H. A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-10-15
- Volume
- 63
- Issue
- 10
- Pages
- 920-930
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2058296375
- Cited by
- 237
- References
- 0
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.